Surface Oncology To Collaborate With Roche On Immuno-Oncology Study

(RTTNews) – Surface Oncology (SURF) said that it has collaborated with Roche to evaluate SRF388, Surface’s investigational anti-IL-27 antibody, in combination with Roche’s atezolizumab and bevacizumab in patients with treatment-naïve hepatocellular carcinoma or HCC.

In Friday pre-market trade, SURF was trading at $9.41 up $0.35 or 3.86%.